A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer

被引：24
|
作者：
Wainberg, Zev [1 ]
Hecht, J. Randolph [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, GI Oncol Program, Los Angeles, CA 90095 USA
来源：
CLINICAL COLORECTAL CANCER | 2006年 / 5卷 / 05期
关键词：
epidermal growth factor receptor; 5-fluorouracil; irinotecan; leucovorin; oxaliplatin; vascular endothelial growth factor;
D O I：
10.3816/CCC.2006.n.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：363 / 367
页数：5
相关论文
共 50 条
  • [21] Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma
    Cote, Gregory Michael
    Chawla, Sant P.
    Demetri, George
    Kasper, Bernd
    Jones, Robin Lewis
    Broto, Javier Martin
    Wooley, Joseph
    Weiss, Mia C.
    Tafuto, Salvatore
    Badalamenti, Giuseppe
    Carrasco-Garcia, Irene
    Peinado, Paloma
    Blay, Jean-Yves
    Boggio, Gaston
    Fernandez, Cristian Marcelo
    Nieto, Antonio
    Kahatt, Carmen Maria
    Zeaiter, Ali Hassan
    Le Cesne, Axel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Irinotecan/capecitabine with or without bevacizumab in metastatic colorectal cancer: Results of a prospective open-label phase iv trial
    Sprinzl, M.
    Kanzler, S.
    Abdelfatah, M.
    Adami, B.
    Ehscheid, P.
    Flieger, D.
    Goedderz, W.
    Teufel, A.
    Galle, P.
    Moehler, M.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII44 - VII45
  • [23] Irinotecan/capecitabine with or without bevacizumab in metastatic colorectal cancer: Results of a prospective open-label phase IV trial
    Moehler, M.
    Sprinzi, M. F.
    Abdelfatah, M.
    Adami, B.
    Ehscheid, P.
    Flieger, D.
    Goedderz, W.
    Majer, C.
    Galle, P. R.
    Kanzler, S.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 170 - 171
  • [24] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [25] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Cartwright, TH
    Lopez, T
    Vukelja, SJ
    Encarnacion, C
    Boehm, KA
    Asmar, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S
  • [26] Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
    Qin, Shukui
    Bi, Feng
    Gu, Shanzhi
    Bai, Yuxian
    Chen, Zhendong
    Wang, Zishu
    Ying, Jieer
    Lu, Yinying
    Meng, Zhiqiang
    Pan, Hongming
    Yang, Ping
    Zhang, Helong
    Chen, Xi
    Xu, Aibing
    Cui, Chengxu
    Zhu, Bo
    Wu, Jian
    Xin, Xiaoli
    Wang, Jufeng
    Shan, Jinlu
    Chen, Junhui
    Zheng, Zhendong
    Xu, Li
    Wen, Xiaoyu
    You, Zhenyu
    Ren, Zhenggang
    Liu, Xiufeng
    Qiu, Meng
    Wu, Liqing
    Chen, Feng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3002 - +
  • [27] An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan
    Lee, Kuan-Der
    Chen, Hong-Hwa
    Wang, Hwei-Ming
    Tsao, Chao-Jung
    Hsu, Tzu-Chi
    Chiu, Chang-Fang
    Su, Wu-Chou
    Wang, Jeng-Yi
    [J]. ONCOLOGY, 2013, 84 (05) : 299 - 304
  • [28] Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
    Robertson, Jane D.
    Botwood, Nick A.
    Rothenberg, Mace L.
    Schmoll, Hans-Joachim
    [J]. CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 59 - 60
  • [29] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    [J]. MEDICINE, 2016, 95 (51) : e4531
  • [30] Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer
    Schofield, P.
    Stockler, M.
    Zannino, D.
    Wong, N.
    Ransom, D.
    Moylan, E.
    Simes, R. J.
    Price, T. J.
    Tebbutt, N. C.
    Jefford, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345